WO2009015284A3 - Protéines de liaison à un antigène de récepteur d'il-18 - Google Patents

Protéines de liaison à un antigène de récepteur d'il-18 Download PDF

Info

Publication number
WO2009015284A3
WO2009015284A3 PCT/US2008/071047 US2008071047W WO2009015284A3 WO 2009015284 A3 WO2009015284 A3 WO 2009015284A3 US 2008071047 W US2008071047 W US 2008071047W WO 2009015284 A3 WO2009015284 A3 WO 2009015284A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen binding
binding proteins
receptor antigen
receptor
same
Prior art date
Application number
PCT/US2008/071047
Other languages
English (en)
Other versions
WO2009015284A8 (fr
WO2009015284A2 (fr
Inventor
Dirk E. Smith
John E. Sims
Jeffrey T. Mcgrew
Marek Z. Kubin
Duncan Cochrane
Louise Conroy
Original Assignee
Amgen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA201000238A priority Critical patent/EA016783B1/ru
Priority to EP08826644A priority patent/EP2178917A4/fr
Priority to AU2008279127A priority patent/AU2008279127B2/en
Priority to BRPI0813016A priority patent/BRPI0813016A2/pt
Application filed by Amgen, Inc. filed Critical Amgen, Inc.
Priority to JP2010518389A priority patent/JP2010534478A/ja
Priority to US12/670,112 priority patent/US8257707B2/en
Priority to CA2693503A priority patent/CA2693503A1/fr
Priority to CN2008800254509A priority patent/CN101835489B/zh
Publication of WO2009015284A2 publication Critical patent/WO2009015284A2/fr
Publication of WO2009015284A8 publication Critical patent/WO2009015284A8/fr
Publication of WO2009015284A3 publication Critical patent/WO2009015284A3/fr
Priority to IL202833A priority patent/IL202833A0/en
Priority to ZA2010/01140A priority patent/ZA201001140B/en
Priority to US13/589,984 priority patent/US8540993B2/en
Priority to US14/017,014 priority patent/US20140093915A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

L'invention propose des protéines de liaison à un antigène de récepteur d'IL-18 et des polynucléotides codant celles-ci. Des vecteurs d'expression et des cellules hôtes comportant ceux-ci pour la production des protéines de liaison à un antigène sont également proposés. En outre, sont proposés des compositions et des procédés pour diagnostiquer et traiter des maladies provoquées par le récepteur d'IL-18.
PCT/US2008/071047 2007-07-24 2008-07-24 Protéines de liaison à un antigène de récepteur d'il-18 WO2009015284A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
US12/670,112 US8257707B2 (en) 2007-07-24 2008-07-24 IL-18 receptor antigen binding proteins
AU2008279127A AU2008279127B2 (en) 2007-07-24 2008-07-24 IL-18 receptor antigen binding proteins
BRPI0813016A BRPI0813016A2 (pt) 2007-07-24 2008-07-24 "proteínas de ligação de antígeno ao receptor de il-18"
CN2008800254509A CN101835489B (zh) 2007-07-24 2008-07-24 Il-18受体抗原结合蛋白
JP2010518389A JP2010534478A (ja) 2007-07-24 2008-07-24 Ｉｌ−１８受容体抗原結合タンパク質
EP08826644A EP2178917A4 (fr) 2007-07-24 2008-07-24 Protéines de liaison à un antigène de récepteur d'il-18
CA2693503A CA2693503A1 (fr) 2007-07-24 2008-07-24 Proteines de liaison a un antigene de recepteur d'il-18
EA201000238A EA016783B1 (ru) 2007-07-24 2008-07-24 Антигенсвязывающие белки для il-18 рецептора и их применение
IL202833A IL202833A0 (en) 2007-07-24 2009-12-20 Il-18 receptor antigen binding proteins
ZA2010/01140A ZA201001140B (en) 2007-07-24 2010-02-17 Il-18 receptor antigen binding proteins
US13/589,984 US8540993B2 (en) 2007-07-24 2012-08-20 Methods of treatment using IL-18 receptor antigen binding proteins
US14/017,014 US20140093915A1 (en) 2007-07-24 2013-09-03 Il-18 receptor antigen binding proteins

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US95169207P 2007-07-24 2007-07-24
US95169107P 2007-07-24 2007-07-24
US60/951,691 2007-07-24
US60/951,692 2007-07-24
US7314208P 2008-06-17 2008-06-17
US61/073,142 2008-06-17

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/670,112 A-371-Of-International US8257707B2 (en) 2007-07-24 2008-07-24 IL-18 receptor antigen binding proteins
US13/589,984 Division US8540993B2 (en) 2007-07-24 2012-08-20 Methods of treatment using IL-18 receptor antigen binding proteins

Publications (3)

Publication Number Publication Date
WO2009015284A2 WO2009015284A2 (fr) 2009-01-29
WO2009015284A8 WO2009015284A8 (fr) 2009-07-02
WO2009015284A3 true WO2009015284A3 (fr) 2009-10-01

Family

ID=40282148

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/071047 WO2009015284A2 (fr) 2007-07-24 2008-07-24 Protéines de liaison à un antigène de récepteur d'il-18

Country Status (17)

Country Link
US (3) US8257707B2 (fr)
EP (1) EP2178917A4 (fr)
JP (2) JP2010534478A (fr)
KR (1) KR20100049535A (fr)
CN (1) CN101835489B (fr)
AR (1) AR067666A1 (fr)
AU (1) AU2008279127B2 (fr)
BR (1) BRPI0813016A2 (fr)
CA (1) CA2693503A1 (fr)
CL (1) CL2008002153A1 (fr)
EA (1) EA016783B1 (fr)
IL (1) IL202833A0 (fr)
PE (1) PE20090518A1 (fr)
SG (1) SG183070A1 (fr)
TW (1) TWI436778B (fr)
WO (1) WO2009015284A2 (fr)
ZA (1) ZA201001140B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
KR101603001B1 (ko) 2010-08-25 2016-03-11 에프. 호프만-라 로슈 아게 Il-18r1에 대한 항체 및 그의 용도
TWI797443B (zh) 2012-05-30 2023-04-01 日商中外製藥股份有限公司 抗原結合分子之篩選或製造方法
US8821242B2 (en) 2012-07-25 2014-09-02 Lumos Labs, Inc. Systems and methods for enhancing cognition
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (fr) 2013-03-15 2014-09-18 Amgen Inc. Polypeptides inhibiteurs spécifiques à des inhibiteurs wnt
KR102085179B1 (ko) * 2013-05-07 2020-04-16 삼성전자주식회사 디바이스의 위치에 기초한 콘텐트 제공 시스템 및 방법
AU2014318017B2 (en) 2013-09-05 2020-02-06 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
JP7060317B2 (ja) 2013-12-04 2022-04-26 中外製薬株式会社 化合物の濃度に応じて抗原結合能の変化する抗原結合分子及びそのライブラリ
AU2015259053B2 (en) 2014-05-16 2020-12-24 Amgen Inc. Assay for detecting Th1 and Th2 cell populations
US10792100B2 (en) 2014-08-20 2020-10-06 Covidien Lp Systems and methods for spherical ablations
KR20160047889A (ko) * 2014-10-23 2016-05-03 삼성전자주식회사 전자 장치 및 피공유자 추천 서비스 운용 방법
JP2020513813A (ja) 2017-03-14 2020-05-21 アムジエン・インコーポレーテツド 細胞培養において産生される抗体の総非フコシル化グリコフォームの調節
JP2021519068A (ja) 2018-03-26 2021-08-10 アムジェン インコーポレイテッド 細胞培養において産生される抗体の総非フコシル化グリコフォーム
WO2019242655A1 (fr) * 2018-06-19 2019-12-26 Shanghaitech University Anticorps humains dirigés contre le récepteur alpha et bêta de l'interleukine 18 humaine
US11396546B2 (en) * 2018-07-13 2022-07-26 Alector Llc Anti-Sortilin antibodies and methods of use thereof
US20220349898A1 (en) 2019-09-26 2022-11-03 Amgen Inc. Methods of producing antibody compositions
US20230273126A1 (en) 2020-06-04 2023-08-31 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
MX2023004364A (es) 2020-10-15 2023-05-03 Amgen Inc Glucanos no emparejados relativos en metodos de produccion de anticuerpos.
CN114736291B (zh) * 2021-01-07 2023-08-11 中国科学院微生物研究所 特异性结合发热伴血小板减少综合征病毒的囊膜蛋白Gn的人源单克隆抗体及其用途
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
AU2022361382A1 (en) 2021-10-05 2024-03-28 Amgen Inc. Fc-gamma receptor ii binding and glycan content
CN117177999B (zh) * 2022-01-14 2024-07-05 和径医药科技（上海）有限公司 一种靶向IL-18Rβ的抗体及其应用
WO2023215725A1 (fr) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions et méthodes pour l'immunothérapie cellulaire
WO2024040195A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027279A1 (fr) * 1999-10-12 2001-04-19 Cambridge Antibody Technology Anticorps monoclonaux anti-adipocytes humains et leur utilisation
US20030059937A1 (en) * 2000-06-16 2003-03-27 Ruben Steven M. Antibodies that immunospecifically bind BLyS
US20040018198A1 (en) * 2001-12-03 2004-01-29 Jean Gudas Antibodies against carbonic anydrase IX (CA IX) tumor antigen
US20040023336A1 (en) * 2001-10-26 2004-02-05 Heavner George A. Mut-IL-18 or Mut-IL-18R proteins, antibodies, compositions, methods and uses
US20070025992A1 (en) * 2003-07-18 2007-02-01 Mochida Pharmaceutical Co., Ltd Monoclonal antibody against platelet membrane glycoprotein VI

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776731A (en) * 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
US7141393B2 (en) * 1996-12-26 2006-11-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18-receptor proteins
NZ505499A (en) * 1998-01-23 2002-07-26 Immunex Corp Accessory protein-like DNA and polypeptides
DK1047781T3 (da) * 1998-01-23 2004-12-06 Immunex Corp IL-18-receptorer
WO2000012555A1 (fr) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Proteine de liaison de l'interleukine 18
IL131047A0 (en) 1999-07-22 2001-01-28 Yeda Res & Dev Use of il-18 inhibitors
EP1257585A2 (fr) 2000-02-10 2002-11-20 Basf Aktiengesellschaft Anticorps de liaison de l'interleukine 18 humaine et procedes de preparation et d'utilisation
CA2422881A1 (fr) 2000-10-13 2002-04-18 Uab Research Foundation Anticorps en chaine simple de recepteur de facteur de croissance anti-epidermique humain
WO2002032374A2 (fr) * 2000-10-18 2002-04-25 Immunex Corporation Methodes de traitement de troubles induits par l'il-18
ES2334773T3 (es) 2001-05-16 2010-03-16 Yeda Research And Development Co. Ltd. Uso de inhibidores de il-18 para el tratamiento o prevencion de la sepsis.
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
JP5595632B2 (ja) * 2004-07-16 2014-09-24 敦生 関山 Ｉｌ−１８レセプターアンタゴニスト、および当該アンタゴニストを含む薬学的組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001027279A1 (fr) * 1999-10-12 2001-04-19 Cambridge Antibody Technology Anticorps monoclonaux anti-adipocytes humains et leur utilisation
US20030059937A1 (en) * 2000-06-16 2003-03-27 Ruben Steven M. Antibodies that immunospecifically bind BLyS
US20040023336A1 (en) * 2001-10-26 2004-02-05 Heavner George A. Mut-IL-18 or Mut-IL-18R proteins, antibodies, compositions, methods and uses
US20040018198A1 (en) * 2001-12-03 2004-01-29 Jean Gudas Antibodies against carbonic anydrase IX (CA IX) tumor antigen
US20070025992A1 (en) * 2003-07-18 2007-02-01 Mochida Pharmaceutical Co., Ltd Monoclonal antibody against platelet membrane glycoprotein VI

Also Published As

Publication number Publication date
EP2178917A4 (fr) 2012-03-28
CA2693503A1 (fr) 2009-01-29
WO2009015284A8 (fr) 2009-07-02
AR067666A1 (es) 2009-10-21
TW200927167A (en) 2009-07-01
CL2008002153A1 (es) 2009-06-05
AU2008279127B2 (en) 2014-03-27
PE20090518A1 (es) 2009-04-25
US8257707B2 (en) 2012-09-04
US20140093915A1 (en) 2014-04-03
US8540993B2 (en) 2013-09-24
CN101835489B (zh) 2013-10-16
JP2010534478A (ja) 2010-11-11
BRPI0813016A2 (pt) 2015-12-15
AU2008279127A1 (en) 2009-01-29
US20130034569A1 (en) 2013-02-07
US20110014201A1 (en) 2011-01-20
EA201000238A1 (ru) 2010-08-30
KR20100049535A (ko) 2010-05-12
JP2015015957A (ja) 2015-01-29
CN101835489A (zh) 2010-09-15
ZA201001140B (en) 2011-03-30
SG183070A1 (en) 2012-08-30
EP2178917A2 (fr) 2010-04-28
WO2009015284A2 (fr) 2009-01-29
IL202833A0 (en) 2011-08-01
TWI436778B (zh) 2014-05-11
EA016783B1 (ru) 2012-07-30

Similar Documents

Publication Publication Date Title
WO2009015284A8 (fr) Protéines de liaison à un antigène de récepteur d'il-18
WO2006113277A3 (fr) Ciblage de multiples voies angiogenes pour le traitement du cancer utilisant des recepteurs solubles de tyrosine kinase
IL196478B (en) Humanized antibodies and their fragments that bind amyloid beta and nucleic acids, vectors and cells that produce them, as well as compound mixtures and their relevant therapeutic uses
WO2014081944A3 (fr) Molécules de liaison à domaine d'egfr et de c-met-fibronectine type iii
WO2009083009A3 (fr) Anticorps monoclonaux anti-cd32b
MY156286A (en) Human il-23 antigen binding proteins
WO2009061996A3 (fr) Anticorps qui se lient à la cellule dendritique et épithéliale 205 (dec-205) humaine
WO2006074435A3 (fr) Polypeptides possedant une activite de cellobiohydrlase et des polynucleotides codant ceux-ci
WO2011020783A3 (fr) Immunoconjugués ciblés
AU2013205271B2 (en) Human CGRP receptor binding proteins
WO2007115201A8 (fr) Polypeptides ayant une activité endoglucanase et polynucléotides encodant lesdits polypeptides
WO2008077945A3 (fr) Séquences d'acides aminés dirigées contre des chimiokines et polypeptides comprenant celles-ci pour le traitement de maladies et de troubles liés aux chimiokines
WO2007067992A3 (fr) Anticorps monoclonaux humains se liant au fucosyl-gm1, et procedes d'utilisation de l'anti-fucosyl-gm1
WO2007077028A3 (fr) Anticorps dirigés contre le her-3 et leurs utilisations
WO2007067991A3 (fr) Anticorps monoclonaux humains se fixant a l'o8e
WO2010129917A3 (fr) Anticorps anti-cd100 et leurs méthodes d'utilisation
WO2011069164A3 (fr) Polypeptides chimériques et hybrides de facteur viii-fc, et procédés d'utilisation de ceux-ci
WO2014106015A3 (fr) Compositions protéiques à liaison multivalente
WO2009155535A3 (fr) Compositions, procédés et kits permettant d’obtenir une réponse immunitaire
WO2006089230A3 (fr) Anticorps monoclonaux humains diriges contre l'antigene d'enveloppe specifique de la prostate
WO2011053763A3 (fr) Antagonistes de l'il-17a
WO2008106646A3 (fr) Procédés et formulations pour une thérapie génique topique
WO2013043933A3 (fr) Protéines de liaison à un antigène cd27l
IL192277A (en) Pharmaceutical compounds with resistance to cea soluble, specific bivalve-specific antibodies that bind cea, nucleic acid sequences encoding the antibodies, vectors and surrogate cells containing the nucleic acids, as well as processes for their creation, uses and compatible kits
WO2007041635A3 (fr) Variants de fc dotés de propriétés de liaison aux récepteurs fc optimisées

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880025450.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08826644

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008279127

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 52/CHENP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20107000286

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2008279127

Country of ref document: AU

Date of ref document: 20080724

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2693503

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/000789

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2010518389

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 201000238

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2008826644

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12670112

Country of ref document: US

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0813016

Country of ref document: BR

Free format text: IDENTIFIQUE O SIGNATARIO DAS PETICOES DO PEDIDO E COMPROVE QUE O MESMO TEM PODERES PARA ATUAR EM NOME DO DEPOSITANTE, UMA VEZ QUE BASEADO NO ARTIGO 216 DA LEI 9.279/1996 DE 14/05/1996 (LPI) "OS ATOS PREVISTOS NESTA LEI SERAO PRATICADOS PELAS PARTES OU POR SEUS PROCURADORES, DEVIDAMENTE QUALIFICADOS."

ENP Entry into the national phase

Ref document number: PI0813016

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100121